Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969 · see citing works

Global prevalence of dementia: a Delphi consensus study

Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336 · see citing works

Defining the clinical course of multiple sclerosis

LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,687 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Practice parameter: Management of dementia (an evidence-based review) [RETIRED]

Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,703 · see citing works

Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · see citing works

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works

Linguistic Ability in Early Life and Cognitive Function and Alzheimer's Disease in Late Life: Findings From the Nun Study

Snowdon, D. A. (1996) · JAMA · doi:10.1001/jama.1996.03530310034029 · Cited by 696 · see citing works

Cerebrospinal Fluid in Diseases of the Nervous System.

Lascelles, P. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-517_1 · Cited by 667 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy

Tang‐Wai, D. F., Graff‐Radford, N. R., Boeve, B. F., Dickson, D. W., Parisi, J. E., Crook, R., Caselli, R. J., Knopman, D. S., & Petersen, R. C. (2004) · Neurology · doi:10.1212/01.wnl.0000140289.18472.15 · Cited by 624 · see citing works

Tau and Aβ42 in Cerebrospinal Fluid from Healthy Adults 21–93 Years of Age: Establishment of Reference Values

Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436 · see citing works

Cerebrospinal Fluid in Diseases of the Nervous System

Pollay, M. (1993) · Neurosurgery · doi:10.1227/00006123-199302000-00029 · Cited by 392 · see citing works

Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works

A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · see citing works

Progressive posterior cortical dysfunction

Renner, J. A., Burns, J. M., Hou, C. E., McKeel, D. W., Storandt, M., & Morris, J. C. (2004) · Neurology · doi:10.1212/01.wnl.0000140290.80962.bf · Cited by 311 · see citing works

Standardization of measurement of β-amyloid_(1-42)in cerebrospinal fluid and plasma

Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301 · see citing works

Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker

Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260 · see citing works

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

Engelborghs, S., de Vreese, K., de Casteele, T. V., Vanderstichele, H., Everbroeck, B. V., Cras, P. P., Martin, J., Vanmechelen, E., & Deyn, P. P. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 256 · see citing works

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H. S., Anckarsäter, R., Andreasen, N., Zetterberg, H., Andréasson, U., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/986310 · Cited by 233 · see citing works

Safety and Acceptability of the Research Lumbar Puncture

Peskind, E. R., Riekse, R. G., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C. S., Chabal, C., Vavrek, D. A., Raskind, M. A., et al. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000194014.43575.fd · Cited by 191 · see citing works

Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

Schoonenboom, N. S. M., Pijnenburg, Y. A. L., Mulder, C., Rosso, S. M., van Elk, E. J., van Kamp, G. J., Swieten, J. C. V., & Scheltens, P. (2004) · Neurology · doi:10.1212/01.wnl.0000123249.58898.e0 · Cited by 181 · see citing works

Access to diagnostic evaluation and treatment for dementia in Europe

Waldemar, G., Phung, T. K. T., Burns, A. S., Georges, J., Hansen, F. R., Iliffe, S., Marking, C., Rikkert, M. G. M. O., Selmès, J., Stoppe, G., et al. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1652 · Cited by 177 · see citing works

Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice

Schoonenboom, N. S. M., Mulder, C., Vanderstichele, H., van Elk, E.-J., Kok, A., van Kamp, G. J., Scheltens, P., & Blankenstein, M. A. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039735 · Cited by 165 · see citing works

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides

Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 143 · see citing works

Low frequency of post-lumbar puncture headache in demented patients

Blennow, K., Wallin, A., & Häger, O. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04221.x · Cited by 130 · see citing works

Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults

Stomrud, E., Hansson, O., Zetterberg, H., Blennow, K., Minthon, L., & Londos, E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.316 · Cited by 116 · see citing works

Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients

Zetterberg, H., Tullhög, K., Hansson, O., Minthon, L., Londos, E., & Blennow, K. (2010) · European Neurology · doi:10.1159/000311703 · Cited by 108 · see citing works

Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides

Bibl, M., Esselmann, H., Otto, M., Lewczuk, P., Cepek, L., Rüther, E., Kornhuber, J., & Wiltfang, J. (2004) · Electrophoresis · doi:10.1002/elps.200305992 · Cited by 91 · see citing works

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren, M., Andreasen, N., & Blennow, K. (2003) · Clinica chimica acta; international journal of clinical chemistry · doi:10.1016/s0009-8981(03)00121-9 · Cited by 88 · see citing works

CSF biomarkers in posterior cortical atrophy

Seguin, J., Formaglio, M., Perret‐Liaudet, A., Quadrio, I., Tholance, Y., Rouaud, O., Thomas-Antérion, C., Croisile, B., Mollion, H., Moreaud, O., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821ccc98 · Cited by 84 · see citing works

Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process?

Carrette, O., Burkhard, P. R., Hughes, S., Hochstrasser, D. F., & Sanchez, J. (2005) · PROTEOMICS · doi:10.1002/pmic.200402039 · Cited by 83 · see citing works

Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation

Chaigneau, C., Cabioch, T., Beaumont, K., & Betsou, F. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.160 · Cited by 78 · see citing works

Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients

Rami, L., Fortea, J., Bosch, B., Solé‐Padullés, C., Lladó, A., Iranzo, Á., Sánchez‐Valle, R., & Molinuevo, J. L. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101422 · Cited by 76 · see citing works

CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry

Blennow, K., & Vanmechelen, E. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00086-8 · Cited by 73 · see citing works

Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

Hort, J., Bartoš, A., Pirttilä, T., & Scheltens, P. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02753.x · Cited by 73 · see citing works

Selective pathological changes of the periaqueductal gray matter in Alzheimer's disease

Parvizi, J., Hoesen, G. W. V., & Damásio, A. R. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 70 · see citing works

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β(1-42) , Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

Teunissen, C. E., Verwey, N. A., Kester, M. I., van Uffelen, K. W. J., & Blankenstein, M. A. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/635053 · Cited by 70 · see citing works

Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease

Poceta, J. S., Parsons, L., Engelland, S., & Kripke, D. F. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2007.11.002 · Cited by 68 · see citing works

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

Bastard, N. L., Martin, J., Vanmechelen, E., Vanderstichele, H., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.017 · Cited by 67 · see citing works

Creutzfeldt-Jakob disease: diagnostic utility of 14–3–3 protein immunodetection in cerebrospinal fluid

Collins, S. J., Boyd, A., Fletcher, A. A., Gonzales, M. F., McLean, C., Byron, K., & Masters, C. L. (2000) · Journal of Clinical Neuroscience · doi:10.1054/jocn.1999.0193 · Cited by 66 · see citing works

Pre‐analytical influence on the low molecular weight cerebrospinal fluid proteome

Berven, F. S., Kroksveen, A. C., Berle, M., Rajalahti, T., Flikka, K., Arneberg, R., Myhr, K., Vedeler, C. A., Kvalheim, O. M., & Ulvik, R. J. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700126 · Cited by 60 · see citing works

Severity of family distress of schizophrenia—fact or artifact?

Damodaran, S. S. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03443.x · Cited by 57 · see citing works

Cerebrospinal Fluid in Diseases of the Nervous System, 2nd Ed.

Harik, S. I. (1994) · Neurology · doi:10.1212/wnl.44.8.1562 · Cited by 57 · see citing works

Preanalytical Sample Handling and Sample Stability Testing for the Neurochemical Dementia Diagnostics

Zimmermann, R., Lelental, N., Ganslandt, O., Maler, J. M., Kornhuber, J., & Lewczuk, P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110212 · Cited by 56 · see citing works

Spectrophotometry for Cerebrospinal Fluid Pigment Analysis

Petzold, A., Sharpe, L. T., & Keir, G. (2006) · Neurocritical Care · doi:10.1385/ncc:4:2:153 · Cited by 53 · see citing works

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20

Pica-Mendez, A. M., Tanen, M., Dallob, A. L., Tanaka, W. K., & Laterza, O. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.019 · Cited by 43 · see citing works

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic

Kester, M. I., Boelaarts, L., Bouwman, F. H., Vogels, R. L. C., Groot, E. R., van Elk, E. J., Blankenstein, M. A., van der Flier, W. M., & Scheltens, P. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000313534 · Cited by 41 · see citing works

Endogeneous peptide profiling of cerebrospinal fluid by MALDI‐TOF mass spectrometry: Optimization of magnetic bead‐based peptide capture and analysis of preanalytical variables

Jiménez, C. R., Simmelink, M. J. A., Pham, T. V., van der Voort, L. F., & Teunissen, C. E. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700330 · Cited by 37 · see citing works

Biomarkers for Early Diagnosis of Alzheimer's Disease

Galimberti, D., & Scarpini, E. A. (2008) · Cited by 32 · see citing works

Alzheimer’s disease biomarkers: from concept to clinical utility

Vanderstichele, H., Meyer, G. D., Shapiro, F. L., Engelborghs, S., Deyn, P. P. D., Shaw, L., & Trojanowski, J. Q. (2008) · Cited by 29 · see citing works

Definitions and diagnostic criteria

Cummings, J. L. (2006) · CRC Press eBooks · doi:10.3109/9780203931714-3 · Cited by 26 · see citing works

Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?

Zetterberg, H. (2008) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488908784534595 · Cited by 15 · see citing works

P4‐076: Sampling Tube, a Critical Factor in Alzheimer’s Disease Biomarker Standardization

Perret‐Liaudet, A., Pelpel, M., Lehmann, S., Schraen‐Maschke, S., Vanderstichele, H., Quadrio, I., Tholance, Y., Zorzi, W., & Coudreuse, A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.08.137 · Cited by 6 · see citing works

The Amyloid-β Pathway in Alzheimer’s Disease

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works

Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET

Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · see citing works

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522 · see citing works

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid

Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401 · see citing works

CSF biomarker variability in the Alzheimer's Association quality control program

Mattsson, N., Andréasson, U., Persson, S., Carrillo, M. C., Collins, S. J., Chalbot, S., Cutler, N. E., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 383 · see citing works

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374 · see citing works

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375 · see citing works

Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343 · see citing works

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramı́rez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 308 · see citing works

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258 · see citing works

Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine

Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Deerlin, V. M. V., Lee, V. M. ‐., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 262 · see citing works

Amyloid‐β efflux from the central nervous system into the plasma

Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 250 · see citing works

Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study

Sharma, R. A., Varga, A. W., Bubu, O. M., Pirraglia, E., Kam, K., Parekh, A., Wohlleber, M. E., Miller, M. D., Andrade, A. G., Lewis, C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0704oc · Cited by 246 · see citing works

MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease

Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236 · see citing works

Influence of comorbidities in idiopathic normal pressure hydrocephalus — research and clinical care. A report of the ISHCSF task force on comorbidities in INPH

Malm, J., Graff‐Radford, N. R., Ishikawa, M., Kristensen, B. W., Leinonen, V., Mori, E., Owler, B., Tullberg, M., Williams, M. A., & Relkin, N. R. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-22 · Cited by 228 · see citing works

Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial

Kim, H., Seo, S. W., Chang, J. W., Lee, J. I., Kim, C. H., Chin, J., Choi, S. J., Kwon, H., Yun, H. J., Lee, J. M., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.007 · Cited by 227 · see citing works

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Molinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret‐Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.003 · Cited by 198 · see citing works

Reporting standards for studies of diagnostic test accuracy in dementia

Noel-Storr, A. H., McCleery, J. M., Richard, E., Ritchie, C. W., Flicker, L. A., Cullum, S. J., Davis, D. H. J., Quinn, T. J., Hyde, C., Rutjes, A. W., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000621 · Cited by 194 · see citing works

Designing the next-generation clinical care pathway for Alzheimer’s disease

Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191 · see citing works

Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays

Lewczuk, P., Lelental, N., Spitzer, P., Maler, J. M., & Kornhuber, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140771 · Cited by 187 · see citing works

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210005 · Cited by 164 · see citing works

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer’s Disease: Potential and Limitations

Cosín‐Tomás, M., Antonell, A., Lladó, A., Alcolea, D. A., Fortea, J., Ezquerra, M., Lleó, A., Martı́, M. J., Pallàs, M., Sánchez‐Valle, R., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0088-8 · Cited by 157 · see citing works

Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction

Evered, L. A., SILBERT, B. S., Scott, D. A., Ames, D. J., Maruff, P. T., & Blennow, K. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000953 · Cited by 152 · see citing works

Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta

Arber, C., Toombs, J., Lovejoy, C., Ryan, N. S., Paterson, R. W., Willumsen, N., Gkanatsiou, E., Portelius, E., Blennow, K., Heslegrave, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0410-8 · Cited by 148 · see citing works

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

Caminiti, S. P., Ballarini, T., Sala, A., Cerami, C., Presotto, L., Santangelo, R., Fallanca, F., Vanoli, E. G., Gianolli, L., Iannaccone, S., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.019 · Cited by 146 · see citing works

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 146 · see citing works

Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 144 · see citing works

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143 · see citing works

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 141 · see citing works

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136 · see citing works

Challenges of multimorbidity of the aging brain: a critical update

Jellinger, K. A., & Attems, J. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1288-x · Cited by 154 · see citing works

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

Toledo, J. B., Shaw, L. M. J., & Trojanowski, J. Q. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt162 · Cited by 135 · see citing works

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133 · see citing works

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 132 · see citing works

Biobanking of CSF: International standardization to optimize biomarker development

Teunissen, C. E., Tumani, H., Engelborghs, S., & Mollenhauer, B. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.12.024 · Cited by 137 · see citing works

Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus

Graff‐Radford, N. R. (2014) · Neurology · doi:10.1212/wnl.0000000000000916 · Cited by 125 · see citing works

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 122 · see citing works

Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease

Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122 · see citing works

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116 · see citing works

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 113 · see citing works

Body fluid biomarkers for multiple sclerosis—the long road to clinical application

Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106 · see citing works

Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders.

Miller, E., Morel, A., Saso, L., & Saluk, J. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666141209160556 · Cited by 86 · see citing works

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease

Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 107 · see citing works

Sleep oscillation-specific associations with Alzheimer’s disease CSF biomarkers: novel roles for sleep spindles and tau

Kam, K., Parekh, A., Sharma, R. A., Andrade, A. G., Lewin, M. P., Castillo, B., Bubu, O. M., Chua, N. J., Miller, M. D., Mullins, A. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0309-5 · Cited by 105 · see citing works

Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS

Oeckl, P., Jardel, C., Salachas, F., Lamari, F., Andersen, P. M., Bowser, R. P., de Carvalho, M. A., Costa, J., Damme, P. V., Gray, E., et al. (2016) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2016.1167913 · Cited by 103 · see citing works

Errors within the total laboratory testing process, from test selection to medical decision-making – A review of causes, consequences, surveillance and solutions

Mrazek, C., Keppel, M. H., Cadamuro, J., Haschke‐Becher, E., Oberkofler, H., Felder, T. K., & Lippi, G. (2020) · Biochemia Medica · doi:10.11613/bm.2020.020502 · Cited by 114 · see citing works

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers

Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99 · see citing works

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 98 · see citing works

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93 · see citing works

Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus

Čarná, M. E., Onyango, I. G., Katina, S., Holub, D., Novotný, J., Nezvedová, M., Jha, D., Nedelská, Z., Lacovich, V., Vyvere, T. V., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12970 · Cited by 96 · see citing works

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

Fourier, A., Portelius, E., Zetterberg, H., Blennow, K., Quadrio, I., & Perret‐Liaudet, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.024 · Cited by 94 · see citing works

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice

Vos, S. J. B., Visser, P. J., Verhey, F. R. J., Aalten, P., Knol, D. L., Ramakers, I. H. G. B., Scheltens, P., Rikkert, M. G. M. O., Verbeek, M. M., & Teunissen, C. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100784 · Cited by 92 · see citing works

Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults

Laws, S. M., Gaskin, S., Woodfield, A., Srikanth, V. K., Bruce, D. G., Fraser, P. E., Porter, T., Newsholme, P., Wijesekara, N., Burnham, S. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09577-4 · Cited by 89 · see citing works

Toward sensitive immuno-based detection of tau protein by surface plasmon resonance coupled to carbon nanostructures as signal amplifiers

Lisi, S., Scarano, S., Fedeli, S., Pascale, E., Cicchi, S., Ravelet, C., Peyrin, É., & Minunni, M. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.078 · Cited by 81 · see citing works

State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease

Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77 · see citing works

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

Vanderstichele, H., Janelidze, S., Demeyer, L., Coart, E., Stoops, E., Herbst, V., Mauroo, K., Brix, B., & Hansson, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160286 · Cited by 80 · see citing works

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey‐Smith, S. R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00595-5 · Cited by 79 · see citing works

Reference Measurement Procedures for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers: Definitions and Approaches With Focus on Amyloid β42

Mattsson, N., Zegers, I., Andréasson, U., Bjerke, M., Blankenstein, M. A., Bowser, R. P., Carrillo, M. C., Gobom, J., Heath, T., Jenkins, R. G., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.39 · Cited by 77 · see citing works

Alzheimer’s Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study

Li, Q., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A. R., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150247 · Cited by 73 · see citing works

Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

Dumurgier, J., Vercruysse, O., Paquet, C., Bombois, S., Chaulet, C., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Pasquier, F., Touchon, J., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.06.006 · Cited by 75 · see citing works

Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers

Wang, J., Fan, D., Li, H.-Y., He, C.-Y., Shen, Y., Zeng, G., Chen, D., Yi, X., Ma, Y., Yu, J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00512-w · Cited by 76 · see citing works

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

Hey, J. A., Kočiš, P., Hort, J., Abushakra, S. R., Power, A., Vyhnálek, M., Yu, Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 73 · see citing works

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

Dorey, A., Perret‐Liaudet, A., Tholance, Y., Fourier, A., & Quadrio, I. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00247 · Cited by 72 · see citing works

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Arslan, B., & Zetterberg, H. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0036 · Cited by 69 · see citing works

Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid

Bastard, N. L., Deyn, P. P. D., & Engelborghs, S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.236679 · Cited by 69 · see citing works

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 69 · see citing works

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations

Mollenhauer, B., Batrla, R., El‐Agnaf, O. M. A., Galasko, D. R., Lashuel, H. A., Merchant, K., Shaw, L. M., Selkoe, D. J., Umek, R. M., Vanderstichele, H., et al. (2017) · Movement Disorders · doi:10.1002/mds.27090 · Cited by 67 · see citing works

Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease

Schmidt, F. M., Mergl, R., Stach, B., Jahn, I., Gertz, H., & Schönknecht, P. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.007 · Cited by 67 · see citing works

Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

Mo, J.-A., Lim, J., Sul, A.-R., Lee, M. Y., Youn, Y. C., & Kim, H.-J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116802 · Cited by 66 · see citing works

Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome

Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 63 · see citing works

Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms – A critical review

Scarano, S., Lisi, S., Ravelet, C., Peyrin, É., & Minunni, M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.08.008 · Cited by 65 · see citing works

Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases

Chen‐Plotkin, A. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.031 · Cited by 60 · see citing works

Pre-analytical factors influencing the stability of cerebrospinal fluid proteins

Simonsen, A. H., Bahl, J. M. C., Danborg, P. B., Lindström, V., Larsen, S. O., GRUBB, A. O., Heegaard, N. H. H., & Waldemar, G. (2013) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.03.011 · Cited by 60 · see citing works

Alzheimer’s Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy

Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 61 · see citing works

Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

Orellana, A., García‐González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende‐Roca, M., Vargas, L., Tartari, J. P., Antonio, E. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136891 · Cited by 57 · see citing works

The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer’s Disease: Results of a Randomized Trial

Berger, M., Nadler, J. W., Friedman, A. H., McDonagh, D. L., Bennett, E. R., Cooter, M. L., Qi, W., Laskowitz, D. T., Ponnusamy, V., Newman, M. F., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151190 · Cited by 59 · see citing works

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease

de Leon, M. J., Pirraglia, E., Osorio, R. S., Glodzik, L., Saint-Louis, L. A., Kim, H.-J., Fortea, J., Fossati, S., LASKA, E. M., Siegel, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191240 · Cited by 58 · see citing works

Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit

Naylor, M. D., Karlawish, J. H., Arnold, S. E., Khachaturian, A. S., Khachaturian, Z. S., Lee, V. M. ‐., Baumgart, M., Banerjee, S., Beck, C. K., Blennow, K., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.08.001 · Cited by 57 · see citing works

Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study

Porter, T., Burnham, S. C., Milicic, L., Savage, G. R., Maruff, P. T., Lim, Y. Y., Li, Q.-X., Ames, D. J., Masters, C. L., Rainey‐Smith, S. R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180713 · Cited by 56 · see citing works

Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic

Sheardová, K., Vyhnálek, M., Nedelská, Z., Laczó, J., Andel, R., Marciniak, R., Cerman, J., Lerch, O., & Hort, J. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030379 · Cited by 57 · see citing works

A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease

Alegret, M., Muñoz, N., Roberto, N., Rentz, D. M., Valero, S., Gil, S., Marquié, M., Hernández, I., Riveros, C., Sanabria, Á., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00594-6 · Cited by 56 · see citing works

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

Bjerke, M., Andréasson, U., Kuhlmann, J., Portelius, E., Pannee, J., Lewczuk, P., Umek, R. M., Vanmechelen, E., Vanderstichele, H., Stoops, E., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0733 · Cited by 56 · see citing works

Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia

Bastard, N. L., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J., & Engelborghs, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121246 · Cited by 55 · see citing works

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Hanes, J., Kováč, A., Kvartsberg, H., Kontseková, E., Fialová, Ľ., Katina, S., Kováčech, B., Stevens, E., Hort, J., Vyhnálek, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010814 · Cited by 54 · see citing works

Amyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies

Slaets, S., Bastard, N. L., Theuns, J., Sleegers, K., Verstraeten, A., Leenheir, E. D., Luyckx, J., Martin, J., Broeckhoven, C. V., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122176 · Cited by 54 · see citing works

A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward

Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 53 · see citing works

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M. A., Lobanov, V. S., Schultz, T., Yang, E., DiBernardo, A., Narayan, V. A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04308.x · Cited by 52 · see citing works

A guide for measurement of circulating metabolic hormones in rodents: Pitfalls during the pre-analytical phase

Bielohuby, M., Popp, S., & Bidlingmaier, M. (2012) · Molecular Metabolism · doi:10.1016/j.molmet.2012.07.004 · Cited by 52 · see citing works

Oxidative Stress and Its Clinical Applications in Dementia

Mao, P. (2012) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/319898 · Cited by 55 · see citing works

Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers

Leitão, M. J., Baldeiras, I., Herukka, S., Pikkarainen, M., Leinonen, V., Simonsen, A. H., Perret‐Liaudet, A., Fourier, A., Quadrio, I., Veiga, P. M., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00153 · Cited by 51 · see citing works

A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium

Somers, C., Struyfs, H., Goossens, J., Niemantsverdriet, E., Luyckx, J., Roeck, N. D., Roeck, E. E. D., Vil, B. B. D., Cras, P. P., Martin, J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151097 · Cited by 50 · see citing works

Cerebrospinal fluid tau proteins in status epilepticus.

Monti, G., Tondelli, M., Giovannini, G., Bedin, R., Nichelli, P. F., Trenti, T., Meletti, S., & Chiari, A. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.04.030 · Cited by 46 · see citing works

The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers

Soares, H. D., Ga̧sior, M., Toyn, J. H., Wang, J.-S., Hong, Q., Berisha, F., Furlong, M. T., Raybon, J. J., Lentz, K. A., Sweeney, F., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232256 · Cited by 48 · see citing works

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 46 · see citing works

Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting

Gervaise-Henry, C., Watfa, G., Albuisson, É., Kolodziej, A., Dousset, B., Olivier, J. L., Jonveaux, T., & Malaplate, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160865 · Cited by 46 · see citing works

Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

Agnello, L., Piccoli, T., Vidali, M., Cuffaro, L., Sasso, B. L., Iacolino, G., Giglio, R. V., Lupo, F., Alongi, P., Bivona, G., et al. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1740939 · Cited by 46 · see citing works

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 19 · see citing works

of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

(2016)

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 122 · see citing works

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136 · see citing works

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

Fourier, A., Portelius, E., Zetterberg, H., Blennow, K., Quadrio, I., & Perret‐Liaudet, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.024 · Cited by 94 · see citing works